Oramed Pharmaceuticals (ORMP) said on Monday it has closed on a $36.9 million strategic investment in Alpha Tau Medical (DRTS), acquiring 14.1 million of the clinical-stage oncology therapeutics company's shares at $2.61 apiece.
Under terms of their collaboration agreement, Oramed will provide investor and shareholder outreach support to Alpha Tau over the next three years along with other business and capital markets expertise. It also will take on an active role in governance at Alpha Tau and will select two new members to the company's board of directors.
After first paying costs associated with the now-completed stock sale, Alpha Tau is planning to use the net proceeds for general corporate purposes, including research and development as well as expanding its production capacities and commercialization of its product candidates.
Alpha Tau shares recently were down over 1% while Oramed was falling about 1.3% during Monday trading.
Price: 2.30, Change: -0.03, Percent Change: -1.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.